We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions (3D)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00233714
First Posted: October 6, 2005
Last Update Posted: November 19, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Cordis Corporation
October 4, 2005
October 6, 2005
November 19, 2009
May 2003
July 2004   (Final data collection date for primary outcome measure)
The primary endpoint is in-stent late lumen loss as measured by QCA at 6 months post-procedure. [ Time Frame: 6 months post-procedure ]
The primary endpoint is in-stent late lumen loss as measured by QCA at 6 months post-procedure.
Complete list of historical versions of study NCT00233714 on ClinicalTrials.gov Archive Site
  • Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure. [ Time Frame: 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure ]
  • Target lesion revascularization (TLR) and target vessel revascularization (TVR) at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure. [ Time Frame: 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure ]
  • Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure. [ Time Frame: 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure ]
  • Device success defined as achievement of a final residual diameter stenosis of <50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used. [ Time Frame: During Index Procedure ]
  • Lesion success defined as the attainment of <50% residual stenosis (by QCA) using any percutaneous method. [ Time Frame: During Index Procedure ]
  • Procedure success defined as achievement of a final diameter stenosis of <50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay. [ Time Frame: During the hospital stay ]
  • In-stent and in-lesion binary restenosis (> 50% diameter stenosis) as measured by QCA at 6 months and 2 years. [ Time Frame: 6 months and 2 years ]
  • In-stent and in-lesion mean percent diameter stenosis (%DS) and minimal lumen. diameter (MLD) measured by QCA post-procedure and at 6 months and 2 years. [ Time Frame: post-procedure and at 6 months and 2 years ]
  • In-lesion late lumen loss measured by QCA at 6 months and 2 years. [ Time Frame: 6 months and 2 years ]
  • Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and 6 months and 2 years. [ Time Frame: post-procedure 6 months and 2 years. ]
  • Glycemic control as measured by HbA1c at baseline, 6, 12, and 24 months. [ Time Frame: baseline, 6, 12, and 24 months ]
  • C-reactive protein levels measured at baseline, 6, 12, and 24 months related to patient outcomes. [ Time Frame: baseline, 6, 12, and 24 months ]
  • · Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure.
  • · Target lesion revascularization (TLR) and target vessel revascularization (TVR) at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure.
  • · Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure.
  • · Device success defined as achievement of a final residual diameter stenosis of <50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.
  • · Lesion success defined as the attainment of <50% residual stenosis (by QCA) using any percutaneous method.
  • · Procedure success defined as achievement of a final diameter stenosis of <50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay.
  • · In-stent and in-lesion binary restenosis (> 50% diameter stenosis) as measured by QCA at 6 months and 2 years.
  • · In-stent and in-lesion mean percent diameter stenosis (%DS) and minimal lumen. diameter (MLD) measured by QCA post-procedure and at 6 months and 2 years.
  • · In-lesion late lumen loss measured by QCA at 6 months and 2 years.
  • · Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and 6 months and 2 years.
  • · Glycemic control as measured by HbA1c at baseline, 6, 12, and 24 months.
  • · C-reactive protein levels measured at baseline, 6, 12, and 24 months related to patient outcomes.
Not Provided
Not Provided
 
Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions
A Randomized Feasibility Study of the Double Dose or Single Dose Sirolimus-Eluting BX VELOCITY Balloon-Expandable Stent for the Treatment of Diabetic Patients With de Novo Native Coronary Artery Lesions(3D)
The main objective of this study is to assess safety and effectiveness of double dose sirolimus-eluting Bx VELOCITY stents in diabetic patients with a de novo native coronary lesion, as compared to single dose sirolimus-eluting Bx VELOCITY™ stents.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Coronary Artery Disease
  • Device: CYPHER Sirolimus-Eluting Coronary Stent
    Single dose Sirolimus-Eluting coronary stent
    Other Name: Cypher Bx Velocity
  • Device: CYPHER Sirolimus-Eluting Coronary Stent
    Double-dose Sirolimus-Eluting coronary stent
    Other Name: Cypher Bx Velocity
  • Active Comparator: 1
    Single-dose Sirolimus-Eluting Coronary stent
    Intervention: Device: CYPHER Sirolimus-Eluting Coronary Stent
  • Active Comparator: 2
    Double-dose Sirolimus-Eluting Coronary stent
    Intervention: Device: CYPHER Sirolimus-Eluting Coronary Stent

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
56
November 2009
July 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The patient must be minimum 18 years of age;
  2. Patients must be previously diagnosed with diabetes with documented treatment with insulin, oral medications, or diet for a minimum of 3 months;
  3. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;
  4. Treatment of one lesion in a native coronary artery. The treated lesion will be the one with the highest % diameter stenosis by visual estimate. Additional study stents may be used for procedural complications such as dissections. Multivessel treatment is permissible in non-target vessels; however, additional lesions may only be treated with commercial stents. If other non-target lesions are treated with commercial stents during the index procedure, they must be successfully treated prior to the study lesion;
  5. The target vessel is 2.5 mm and 3.5mm in diameter (visual estimate);
  6. The target lesion is <30 mm in length (visual estimate) located in a native coronary artery;
  7. Target lesion stenosis is >50% and <100% (TIMI I) (visual estimate);

Exclusion Criteria:

  1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;
  2. Patients admitted for treatment of diabetic ketoacidosis > 2 times in the past six months (Brittle Diabetics);
  3. Ejection fraction 30%;
  4. Impaired renal function (creatinine > 2.0 mg/dL);
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
 
NCT00233714
P03-6318
No
Not Provided
Not Provided
Sid Cohen, MD, VP, Cordis
Cordis Corporation
Not Provided
Principal Investigator: Jose E. Sousa, MD Institute Dante Pazzanese of Cardiology
Cordis Corporation
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP